Qian‐Nan Wang

Qian‐Nan Wang

Auto-generated profile, based on publicly available information

Qian‐Nan Wang

Chinese PLA General Hospital

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in European Journal of Neurology
Verified
Journal Article
Open access
JLJing‐Jie Li
Jing‐Jie Li
XWXiao‐Peng Wang
Xiao‐Peng Wang
QWQian‐Nan Wang
Qian‐Nan Wang
ZKZi‐Qing Kong
Zi‐Qing Kong
CHCong Han
Cong Han
LDLian Duan
Lian Duan
Background: Stroke in children is a global epidemic.Methods: Data on stroke, including incidence, DALYs, mortality, and associated risk factors from 1990 to 2021, were obtained from the Global Burden of Disease (GBD) study, 2021. Estimated annual percentage changes were calculated to evaluate changes in the age‐standardized rates of incidence (ASIR), DALYs (ASDR), and mortality (ASMR), as well as trends by age, sex, and sociodemographic index (SDI). Projections of DALYs to 2050 were made.Results: In 2021, there were 310,133 incident stroke cases, accounting for 24,807 deaths and 2,414,655 DALYs among children and adolescents. The global ASIR, ASDR, and ASMR for stroke were 11.8, 93.9, and 1.0 per 100,000 population, respectively. Middle‐to‐low‐SDI regions accounted for 81.6% of incident cases, 90.2% of DALYs, and 92.7% of deaths. A reversed V‐shaped association was observed between SDI and ASRs. Children < 1 year had the highest ASRs, with rates generally decreasing with age, and the highest incidence of hemorrhagic stroke. Adolescents aged 15–19 years had the highest incidence of ischemic stroke. Non‐optimal temperature contributed the most to the DALYs and death rates for stroke. By 2050, it is projected that 282,404 DALYs will be lost due to stroke.Conclusions: Stroke burden varies by the GBD region, country, age, sex, and SDI. Despite declines in ASRs, stroke remains a significant burden, especially in middle‐to‐low‐SDI regions, among children < 1 year, and among those with intracerebral hemorrhage. Non‐optimal temperature emerges as the leading modifiable risk factor for children stroke; targeted interventions can prevent this.

17 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
QGQingbao Guo
Qingbao Guo
MXManli Xie
Manli Xie
HJHuanhuan Ji
Huanhuan Ji
QWQian‐Nan Wang
Qian‐Nan Wang
QGQingbao Guo
Qingbao Guo
LDLian Duan
Lian Duan
Background: Although hypertension is prevalent in adults with moyamoya disease (MMD) and intracranial hemorrhage significantly worsens prognosis, the impact of hypertension on long‐term outcomes after encephaloduroarteriosynangiosis in hemorrhagic MMD remains unclear; this retrospective cohort study used propensity score matching to compare outcomes between hypertensive and nonhypertensive patients and preliminarily assess the role of blood pressure management. Methods: After propensity score matching, long‐term outcomes post‐ encephaloduroarteriosynangiosis in patients with hemorrhagic MMD with hypertension from January 2010 to December 2018 were analyzed. The clinical and radiological data were collected. Kaplan–Meier curves evaluated the relationship between recurrence‐free survival, overall survival (OS), and hypertension. Univariate and multivariate Cox regression assessed independent factors influencing hematoma recurrence‐free survival and OS. Subgroup analysis of patients with hemorrhagic MMD with hypertension assessed the impact of different blood management on long‐term outcomes. Results: Kaplan–Meier curves showed a significant correlation between hypertension and decreased hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014) during follow‐up. The 5‐year recurrence‐free survival rate did not significantly differ between hypertensive and nonhypertensive groups ( P =0.77). Hypertension was associated with reduced 10‐year hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014). In multivariate analysis, hypertension ( P =0.015), perioperative complications ( P =0.003), and choroidal anastomosis ( P =0.0008) significantly influenced hematoma recurrence‐free survival. Analysis of OS revealed significant differences for hypertension ( P =0.018), follow‐up duration ( P <0.001), choroidal anastomosis ( P =0.041), and initial mRS ( P <0.001). Subgroup analysis showed that optimal blood pressure management significantly reduced hematoma recurrence ( P =0.049) but did not improve OS ( P =0.31). Conclusions: This study highlights significant differences in hematoma recurrence‐free survival and OS between patients with hemorrhagic MMD with and without hypertension. A subgroup analysis of those with hypertension showed that optimal blood pressure control notably lowered hematoma recurrence but did not improve OS. For patients with hemorrhagic MMD with hypertension, optimizing blood pressure alone may be insufficient, emphasizing the importance of personalized integrated strategies for this patient subgroup.

1 June 2026 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
QWQian-Nan Wang
Qian-Nan Wang
XWXiao-Peng Wang
Xiao-Peng Wang
XLXiao-Mei Li
Xiao-Mei Li
JLJing-Jie Li
Jing-Jie Li
ZZZheng-Xing Zou
Zheng-Xing Zou
LDLian Duan
Lian Duan
This cohort study was conducted using prospective and retrospective data to investigate whether indirect encephaloduroarteriosynangiosis (EDAS) revascularization can reduce the risk of rebleeding in adult patients with hemorrhagic moyamoya disease (hMMD). We enrolled adult patients diagnosed with hMMD prospectively and retrospectively. All patients voluntarily chose to undergo EDAS or conservative treatment. The clinical features, angiographic findings, and follow-up outcomes were investigated and analyzed using the Kaplan–Meier survival analysis and Cox proportional hazards regression models to estimate rebleeding risks post-EDAS. Among the 186 patients with hMMD, 123 patients (66.1%) underwent EDAS, and 63 patients (33.9%) received conservative treatment. In the EDAS group, one (0.8%) patient suffered postoperative infarction, 16 patients (13.0%) experienced recurrent cerebral hemorrhage, and three patients (2.4%) died from rebleeding events. In the conservative treatment group, 18 patients (28.6%, p = 0.015) experienced cerebral rebleeding events and seven (11.1%, p = 0.033) died from rebleeding events. According to the Kaplan–Meier analysis, the annual rebleeding incidence rate was 1.4%/year in the EDAS group and 3.6%/year in the conservative treatment group ( p = 0.005, Log-Rank test). Multivariate Cox regression analysis revealed that EDAS surgery was a protective predictor for rebleeding events, while age and the dilation of posterior choroidal artery were positive factors influencing recurrent hemorrhage events. Long-term follow-up results show that, compared to conservative treatment, EDAS revascularization can effectively reduce the rate of recurrent cerebral hemorrhage in adult patients with hMMD.

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
QGQingbao Guo
Qingbao Guo
MXManli Xie
Manli Xie
HWHui Wang
Hui Wang
JLJingjie Li
Jingjie Li
QWQian‐Nan Wang
Qian‐Nan Wang
LDLian Duan
Lian Duan
Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown pathogenesis, partly due to limited access to human cerebral vascular tissue and suitable animal models. Using a large biobank of frozen serum samples, this study aimed to explore molecular signatures of ischemic and hemorrhagic MMD. Methods: Serum from 30 patients with MMD (18 ischemic, 12 hemorrhagic) and 30 matched healthy controls underwent proteomic and metabolomic profiling. Data were analyzed for differential expression, pathway enrichment, and protein–metabolite networks, with adjustment for age, sex, and body mass index. Results: In a separate large Chinese cohort (n=6167), female patients had a higher proportion of hemorrhagic MMD (19.9% versus 16.9%) and a higher prevalence of anterior choroidal artery dilation (15.1% versus 13.2%) than male patients (both P <0.05). At the molecular level, ischemic MMD showed complement C4‐B deficiency and disrupted natural killer cell cytotoxicity; both subtypes shared immunoglobulin perturbations (eg, decreased heavy‐chain variable regions). Sex‐specific alterations included anti–folate‐binding protein, serum amyloid A2, glycolithocholic acid, and estradiol. All omics data are publicly accessible. Conclusions: Integrated serum multiomics defines distinct immune‐related signatures for ischemic and hemorrhagic MMD and reveals sex‐dimorphic molecular pathways. These findings, together with clinical sex differences in disease subtype and vascular anatomy, provide a framework for personalized, sex‐aware management of MMD.